Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The serological status of Solomon Island blood donors in 1995 and in particular the seroprevalence of antibodies to Hepatitis B and C and prevalence of risk factors for these chronic infections was studied. A questionnaire of risk factors for Hepatitis B and C was undertaken. All blood donors had been previously screened for HIV antibody without any positive cases recorded. 598 donors had serum collected of which 36 samples (6.0%) were third generation HCV EIA antibody positive and 3 samples were RIBA positive but none were PCR positive. 25.1% of samples were positive for HBsAg and anti-HBc antibody was found in 84.4%. Elevated ALT levels (>35 U/l) were found in 6.5% of samples but there was no statistically significant association with HCV or HBsAg status. 15.4% were TPHA positive and 5.4% had RPR titers more than or equal to 1. Anti-HTLV-1 antibody was positive in 12.3% randomly selected samples. All 10 positive samples were then found to be antibody indeterminate with Western blot assay. Of the 585 samples with completed questionnaires, analysis of the relationship between anti-HCV status with tattoo status and ear piercing also failed to reach statistical significance. Consistent with other studies from tropical malaria-prone countries, a positive anti-HCV antibody test even by the third generation EIA is probably a false positive test in most cases. In addition, high prevalence rates of HBV, yaws or syphilis infection were demonstrated.
 ...
PMID:The serological status of Solomon Island blood donors. 1077 66

Evidence-based medicine is advocated by WHO and adopted by developed countries for many years. In China, however, the selection of essential medicine and various medical insurance reimbursement schemes medicine is usually based on experts' experience of prescription practice which is under heavy critics resulting from the lack of related comparative efficacy and evidence-based research. The efficacy of Jian'ganle in prevention of drug-induced liver injury (DILI) caused by antituberculotics was evaluated in this study by comparison with Hugan Pian, glucuronolactone and reduced glutathione. Evidence was provided for relevant sectors such as Ministry for Human Resources and Social Security of the People's Republic of China and National Health and Family Planning Commission of the People's Republic of China to select and renew the Essential Medicine List (EML), the new rural cooperative medical scheme in China (NRCMS) list or the reimbursement list of industrial injury insurance. A total of 189 patients with initial pulmonary tuberculosis were divided into four groups who took antituberculotics combined with Jian'ganle, Hugan Pian, glucuronolactone and reduced glutathione respectively. Their liver function profile including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), total protein (TP), albumin (A) and globulin (G) were detected at admission as baseline and after treatment. The Jian'ganle group was compared with the three others by chi-square tests. In an aspect of maintaining bilirubin indexes normal, Jian'ganle was more efficacious than glucuronolactone. And Jian'ganle had a little more efficacy than reduced glutathione to maintain protein indexes normal as well. And the therapeutic regimen of antituberculotics combined with Jian'ganle was the best in treating tuberculosis and preventing DILI at the same time. The study showed that among the four hepatinicas which demonstrated similar prevention of DILI caused by antituberculotics, Jian'ganle has more advantages over the three others to some extent, which provides a reliable basis for health sectors to select and renew the EML, NRCMS List or the reimbursement list of industrial injury insurance.
...
PMID:Efficacy of Jian'ganle () versus Hugan Pian (), glucuronolactone and reduced glutathione in prevention of antituberculosis drug-induced liver injury. 2493 15